INTERNATIONAL PATENT: MBRACE THERAPEUTICS, INC. FILES APPLICATION FOR "ANTIBODY-DRUG CONJUGATES AGAINST THE GLUCOSE-REGULATING PROTEIN 78 (GRP78)"

GENEVA, Aug. 26 -- MBRACE THERAPEUTICS, INC. (4660 La Jolla Village Drive, Suite 895San Diego, California 92122) filed a patent application (PCT/US2025/015431) for "ANTIBODY-DRUG CONJUGATES AGAINST THE GLUCOSE-REGULATING PROTEIN 78 (GRP78)" on Feb 11, 2025. With publication no. WO/2025/174776, the details related to the patent application was published on Aug 21, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): STAQUICINI, Fernanda I. (c/o MBrace Therapeutics, Inc.4660 LaJolla Village Drive, Suite 895San Diego, CA 92122)

Abstract: This disclosure relates to antibodies, binding polypeptides...